A Phase 2 interventional study of Duvelisib in Indolent Non-Hodgkin Lymphoma, sponsored by SecuraBio. Completed at 69 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-07.
Sponsored by SecuraBio · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma [FL], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).
This was an open-label, single-arm safety and efficacy study of duvelisib administered orally to participants who had been diagnosed with iNHL whose disease was refractory to rituximab and to either chemotherapy or RIT.
Approximately 120 participants received 25 milligrams of duvelisib twice daily over the course of 28-day treatment cycles for up to 13 cycles.
After completing 13 treatment cycles of duvelisib, participants continued to receive additional cycles of duvelisib until disease progression or unacceptable toxicity. However, to receive additional cycles of duvelisib beyond 13 cycles, participants must have had evidence of response (complete response [CR] or partial response [PR]) or stable disease according to the International Working Group criteria by the end of Cycle 13.
SecuraBio is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Duvelisib
Phosphoinositide-3-kinase (PI3K) inhibitor
Also known as: Copiktra, IPI-145
Overall Response Rate (ORR)
ORR, defined as the total percentage of participants who had a best overall response of either complete response (CR) or partial response (PR), was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma. ORR is reported with a 2-sided 95% exact confidence interval.
Time frame: Every 8-16 weeks while on treatment with duvelisib for up to 72 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any adverse event that emerged or worsened in the period from the first dose of study treatment to 30 days after the last dose of study treatment. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Every 2-8 weeks for up to 73 months
Duration of Response (DOR)
DOR, defined as the time from the first documentation of response to either progressive disease (PD) or death due to any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.
Time frame: Every 8-16 weeks for up to 72 months
Progression-free Survival (PFS)
PFS, defined as the time from the first dose of study treatment to the first documentation of either Investigator-assessed PD or death resulting from any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.
Time frame: Every 8-16 weeks for up to 72 months
Overall Survival (OS)
OS, defined as the time from the first dose of study treatment to the date of death, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.
Time frame: Every 16 weeks for up to 72 months
Plasma Concentration of Duvelisib and IPI-656
The serum concentration of duvelisib and its main metabolite, IPI-656, are reported for Day 15 of Cycle 1 (C1D15) and Day 1 of Cycle 2 (C2D1) and Day 1 of Cycle 3 (C3D1). Results are reported in nanograms/milliliter (ng/mL).
Time frame: Every 4 weeks for 12 weeks (C1D15: predose, 1 and 4 hours post dose; C2D1 and C3D1: anytime during study visit)
Time to Response (TTR)
TTR, defined as the time from the first dose of study treatment to the first documentation of response, was evaluated by an independent, third-party panel of radiologists and oncologists (Independent Review Committee \[IRC\]) according to the revised IWG Response Criteria for Malignant Lymphoma.
Time frame: First dose to first documentation of complete or partial response (up to 6 months)
This multicenter, multinational study enrolled participants at 56 medical clinics across 12 countries.
| Milestone | Duvelisib |
|---|---|
| Started | 129 |
| Received at least 1 dose of study drug | 129 |
| Completed | 0 |
| Not completed | 129 |
| Withdrew: Disease progression | 1 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Death | 68 |
| Withdrew: Physician decision | 3 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Follow-up completed | 39 |
| Withdrew: Study terminated by the sponsor | 6 |
ORR, defined as the total percentage of participants who had a best overall response of either complete response (CR) or partial response (PR), was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma. ORR is reported with a 2-sided 95% exact confidence interval.
| percentage of participants | Duvelisib |
|---|---|
| Overall Response Rate (ORR) | 59.7 (50.7 to 68.2) |
An adverse event was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any adverse event that emerged or worsened in the period from the first dose of study treatment to 30 days after the last dose of study treatment. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| Participants | Duvelisib |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 128 |
DOR, defined as the time from the first documentation of response to either progressive disease (PD) or death due to any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.
| months | Duvelisib |
|---|---|
| Duration of Response (DOR) | 10.16 (8.78 to 13.61) |
PFS, defined as the time from the first dose of study treatment to the first documentation of either Investigator-assessed PD or death resulting from any cause, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.
| months | Duvelisib |
|---|---|
| Progression-free Survival (PFS) | 9.57 (8.35 to 11.70) |
OS, defined as the time from the first dose of study treatment to the date of death, was evaluated locally (investigator's assessment) according to the revised IWG Response Criteria for Malignant Lymphoma.
| months | Duvelisib |
|---|---|
| Overall Survival (OS) | 28.96 (21.37 to 37.02) |
The serum concentration of duvelisib and its main metabolite, IPI-656, are reported for Day 15 of Cycle 1 (C1D15) and Day 1 of Cycle 2 (C2D1) and Day 1 of Cycle 3 (C3D1). Results are reported in nanograms/milliliter (ng/mL).
| ng/mL | Duvelisib | IPI-656 |
|---|---|---|
| C1D15 Predose | 414 (19 to 4590) | 648 (116 to 6010) |
| C1D15 1 hour post dose | 1175 (206 to 6820) | 641 (160 to 5920) |
| C1D15 4 hours post dose | 852 (233 to 5170) | 714 (230 to 6020) |
| C2D1 | 631 (NA to 4180) | 704 (NA to 10200) |
| C3D1 | 696 (NA to 3540) | 664 (NA to 6850) |
TTR, defined as the time from the first dose of study treatment to the first documentation of response, was evaluated by an independent, third-party panel of radiologists and oncologists (Independent Review Committee \[IRC\]) according to the revised IWG Response Criteria for Malignant Lymphoma.
| month | Duvelisib |
|---|---|
| Time to Response (TTR) | 1.87 (1.71 to 3.65) |
Collected over 73 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Duvelisib | 68/129 (52.7%) | 83/129 (64.3%) | 122/129 (94.6%) |
| Event | Duvelisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 10/129 |
| Febrile neutropeniaBlood and lymphatic system disorders | 9/129 |
| Disease progressionGeneral disorders | 9/129 |
| PneumoniaInfections and infestations | 7/129 |
| ColitisGastrointestinal disorders | 6/129 |
| PancytopeniaBlood and lymphatic system disorders | 4/129 |
| PyrexiaGeneral disorders | 4/129 |
| BronchopneumoniaInfections and infestations | 4/129 |
| Renal failure acuteRenal and urinary disorders | 4/129 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 4/129 |
| Event | Duvelisib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 63/129 |
| NauseaGastrointestinal disorders | 38/129 |
| NeutropeniaBlood and lymphatic system disorders | 37/129 |
| FatigueGeneral disorders | 37/129 |
| AnaemiaBlood and lymphatic system disorders | 36/129 |
| CoughRespiratory, thoracic and mediastinal disorders | 35/129 |
| PyrexiaGeneral disorders | 32/129 |
| ThrombocytopeniaBlood and lymphatic system disorders | 25/129 |
| VomitingGastrointestinal disorders | 22/129 |
| Oedema peripheralGeneral disorders | 22/129 |
Full Analysis Set (FAS): all participants who received at least 1 dose of duvelisib.
| Age, Categorical(Participants) | Duvelisib |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 64 |
| >=65 years | 65 |
| Age, Continuous(years) | Duvelisib |
|---|---|
| Mean | 63.6 ± 11.69 |
| Sex: Female, Male(Participants) | Duvelisib |
|---|---|
| Female | 41 |
| Male | 88 |
| Ethnicity (NIH/OMB)(Participants) | Duvelisib |
|---|---|
| Hispanic or Latino | 3 |
| Not Hispanic or Latino | 118 |
| Unknown or Not Reported | 8 |
| Race/Ethnicity, Customized(Participants) | Duvelisib |
|---|---|
| American Indian or Alaskan Native | 1 |
| Asian | 1 |
| Black or African American | 6 |
| Native Hawaiian or other Pacific Islander | 0 |
| White | 116 |
| Other | 1 |
| Unknown | 2 |
| Missing | 2 |
| Region of Enrollment(participants) | Duvelisib |
|---|---|
| Hungary | 7 |
| United States | 46 |
| Czechia | 9 |
| United Kingdom | 11 |
| Belarus | 10 |
| Spain | 2 |
| Canada | 9 |
| Belgium | 2 |
| Italy | 21 |
| Georgia | 1 |
| France | 6 |
| Bulgaria | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2013 to primary completion in Nov 2020, 89 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvelisib